CAD25.83
0.86% day before yesterday
Toronto, Dec 27, 06:52 pm CET
ISIN
CA0717051076
Symbol
BLCO
Sector

Bausch + Lomb Stock price

CAD25.83
-2.82 9.84% 1M
+5.67 28.13% 6M
+3.16 13.94% YTD
+4.09 18.81% 1Y
+0.33 1.29% 3Y
+0.33 1.29% 5Y
+0.33 1.29% 10Y
Toronto, Closing price Fri, Dec 27 2024
+0.22 0.86%
ISIN
CA0717051076
Symbol
BLCO
Sector

Key metrics

Market capitalization CAD9.10b
Enterprise Value CAD14.97b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.35
P/S ratio (TTM) P/S ratio 1.43
P/B ratio (TTM) P/B ratio 1.02
Revenue growth (TTM) Revenue growth 19.11%
Revenue (TTM) Revenue CAD6.37b
EBIT (operating result TTM) EBIT CAD257.60m
Free Cash Flow (TTM) Free Cash Flow CAD-78.54m
Cash position CAD472.83m
EPS (TTM) EPS CAD-1.42
P/E forward negative
P/S forward 1.35
EV/Sales forward 2.23
Short interest 0.07%
Show more

Is Bausch + Lomb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Bausch + Lomb Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Bausch + Lomb forecast:

6x Buy
40%
8x Hold
53%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Bausch + Lomb forecast:

Buy
40%
Hold
53%
Sell
7%

Financial data from Bausch + Lomb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
6,375 6,375
19% 19%
100%
- Direct Costs 2,902 2,902
18% 18%
46%
3,473 3,473
20% 20%
54%
- Selling and Administrative Expenses 2,160 2,160
25% 25%
34%
- Research and Development Expense 449 449
3% 3%
7%
864 864
17% 17%
14%
- Depreciation and Amortization 607 607
25% 25%
10%
EBIT (Operating Income) EBIT 258 258
0% 0%
4%
Net Profit -500 -500
79% 79%
-8%

In millions CAD.

Don't miss a Thing! We will send you all news about Bausch + Lomb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Head office Canada
CEO Brenton Saunders
Employees 13,300
Founded 1853
Website www.bausch.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today